Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?
Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead.
Overview
Discover how Novo Nordisk (NYSE: NVO) stacks up against Eli Lilly (NYSE: LLY) in the obesity and metabolic race, from GLP‑1 leadership to NASH/MASH optionality and dividend appeal. Watch the video below to see which profile fits your portfolio.
*This video was published on Jun. 26, 2026.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.